Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma‐associated antigen MART‐1/Melan‐A
暂无分享,去创建一个
B. Seliger | J. Karbach | F. Momburg | M. Maeurer | E. Jäger | A. Knuth | C. Castelli | H. Höhn
[1] Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). , 1998, Cancer research.
[2] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[3] M. Lotze,et al. Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pulsed with Synthetic or Natural Tumor Peptides Elicit Tumor‐Specific CTLs In Vitro , 1998, Journal of immunotherapy.
[4] P. Romero,et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.
[5] F. Marincola,et al. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. , 1998, Critical reviews in immunology.
[6] B. Seliger,et al. TAP off--tumors on. , 1997, Immunology today.
[7] F. Marincola. The multiple ways to tumor tolerance. , 1997, Journal of immunotherapy.
[8] H. Eisen,et al. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response. , 1997, International immunology.
[9] J. Karbach,et al. Amino acid substitutions at position 97 in HLA‐A2 segregate cytolysis from cytokine release in MART‐1/Melan‐A peptide AAGIGILTV‐specific cytotoxic T lymphocytes , 1996, European journal of immunology.
[10] B. Stockinger,et al. Expression of a second receptor rescues self-specific T cells from thymic deletion and allows activation of autoreactive effector function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] P. Bruggen,et al. Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.
[12] M. Lotze,et al. TCR usage in CTLs recognizing melanoma/melanocyte antigens. , 1995, Immunology today.
[13] P. Romero,et al. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1 , 1995, The Journal of experimental medicine.
[14] A. Sette,et al. Recognition of multiple peptide cores by a single T cell receptor , 1995, The Journal of experimental medicine.
[15] S. Rowland-Jones,et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Farina,et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Lanzavecchia,et al. Serial triggering of many T-cell receptors by a few peptideMHC complexes , 1995, Nature.
[18] A Sette,et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.
[19] J. Bell,et al. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment , 1995, The Journal of experimental medicine.
[20] M. Lotze,et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.
[21] P. Kourilsky,et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. , 1994, Journal of immunology.
[22] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[23] J. Renauld,et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.
[24] M. Robinson,et al. The human T-cell receptor variable gene segment TCRBV6S1 has two null alleles. , 1994, Human immunology.
[25] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[26] Günter J. Hämmerling,et al. Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.
[27] M. Lotze,et al. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. , 1993, Journal of immunology.
[28] G. Carcelain,et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. , 1993, Cancer research.
[29] S. Roman-Roman,et al. An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.
[30] R. Mulligan,et al. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[32] L. Old,et al. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[33] L. Old,et al. Cell‐mediated cytotoxicity for cultured autologous melanoma cells , 1979, International journal of cancer.